The prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors

Breast

Volumn 18, Issue 6, 2009, Pages 351-355

  Stuart Harris, R ^a   Shadbolt, B ^a   Palmqvist, C ^a   Chaudri Ross, H A ^b  

^a CANBERRA HOSPITAL   (Australia)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

ER; Estrogen receptor; Metastatic breast cancer; PgR; Progesterone receptor; Survival

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ESTROGEN RECEPTOR; LETROZOLE; MEGESTROL ACETATE; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

EID: 71749114406     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2009.09.002     Document Type: Article

References (24)

1. Collett K., Hartveit F., Skjaerven R., and Maehle B.O. Prognostic role of oestrogen and progesterone receptors in patients with breast cancer: relation to age and lymph node status. J Clin Pathol 49 (1996) 920-925
2. Elledge R.M., Green S., Pugh R., Allred D.C., Clark G.M., Hill J., et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a southwest oncology group study. Int J Cancer 89 (2000) 111-117
3. Olivotto I.A., Truong P.T., Speers C.H., Bernstein V., Allan S.J., Kelly S.J., et al. Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol 22 (2004) 1769-1770
4. Osborne C.K., Yochmowitz M.G., Knight III W.A., and McGuire W.L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46 12 Suppl. (1980) 2884-2888
5. Bloom N.D., Tobin E.H., Schreibman B., and Degenshein G.A. The role of progesterone receptors in the management of advanced breast cancer. Cancer 45 (1980) 2992-2997
6. Young P.C., Ehrlich C.E., and Einhorn L.H. Relationship between steroid receptors and response to endocrine therapy and cytotoxic chemotherapy in metastatic breast cancer. Cancer 46 12 Suppl. (1980) 2961-2963
7. Barnes D.M., Harris W.H., Smith P., Millis R.R., and Rubens R.D. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 74 (1996) 1445-1451
8. Ravdin P.M., Green S., Dorr T.M., McGuire W.L., Fabian C., Pugh R.P., et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective southwest oncology group study. J Clin Oncol 10 (1992) 1284-1291
9. Chang J., Clark G.M., Allred D.C., Mohsin S., Chamness G., and Elledge R.M. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumour. Cancer 97 (2003) 545-553
10. Dowsett M., Cuzick J., Wale C., Howell T., Houghton J., and Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 23 (2005) 7512-7517
11. Dowsett M., Allred D.C., Knox J., Quinn E., Salter J., Wale C., et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 26 (2008) 1059-1065
12. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: national cancer institute of Canada clinical trials group MA 17. J Clin Oncol 25 (2007) 2006-2011
13. Viale G., Regan M.M., Maiorano E., Mastropasqua M.G., Dell'Orto P., Rasmussen B.B., et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25 (2007) 3846-3852
14. Early breast cancer trialist's collaborative group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
15. Rakha E.A., El-Sayed M.E., Green A.R., Paish E.C., Powe D.G., Gee J., et al. Biologic and clinical characteristics of breast cancer with single hormone receptor-positive phenotype. J Clin Oncol 25 (2007) 4772-4778
16. Colomer R., Beltran M., Dorcas J., Cortes-Funes H., Hornedo J., Valentin V., et al. It is not time to stop progesterone receptor testing in breast cancer. J Clin Oncol 23 (2005) 3868-3870
17. Saccani Jotti G., Johnston S.R., Salter J., Detre S., and Dowsett M. Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay. J Clin Pathol 47 (1994) 900-905
18. Harvey J.M., Clark G.M., Osborne C.K., and Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17 (1999) 1474-1481
19. Buzdar A., Jonat W., Howell A., Jones S.E., Blomqvist C., Vogel C.L., et al., for the Arimidex study group. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 14 (1996) 2000-2011
20. Dombernowsky P., Smith I., Falkson G., Leonard R., Panasci L., Bellmunt J., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16 (1998) 453-461
21. Gershanovich M., Chaudri H.A., Campos D., Lurie H., Bonaventura A., Jeffrey M., et al. Letrozole, a new oral aromatase inhibitor: randomized trial comparing 2.5 mg daily... 5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol 6 (1998) 639-645
22. Fisher E.R., Sass R., and Fisher B. Pathologic findings from the national surgical adjuvant breast project. Correlations with concordant and discordant estrogen and progesterone receptors. Cancer 59 (1987) 1554-1559
23. Mauri D., Pavlidis N., Polyzos N.P., and Ioannidis J.P.A. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 98 (2006) 1285-1291
24. MacFarlane R., Speers C., Masoudi H., and Chia S. Molecular changes in the primary breast cancer versus relapsed/metastatic lesion from a large population-based database and tissue microarray series. J Clin Oncol 26 May 20 suppl (2008) Abstract 1000